Director, Medical Decision Scientist
Current▪ Supported International Development Market Team to address threat to Toviaz reimbursement by EU Health Authority; led workshop and developed favorable benefit risk conclusion validated and published results with key opinion leaders.▪ Led benefit-risk workshop to guide submission strategy and prepare key messages for communication conclusions to regulators; provided data, key to gaining regulatory approval by assisting team in communicating acceptable level of risk for drug. ▪ Designed online self-service system, enabling teams to complete benefit risk frameworks collaboratively to improve efficiency of drafting and transferring documents into electronic regulatory submission system. ▪ Served as Pfizer Medical decision quality expert and surveyed stakeholders in medical decision forums to establish best practices and identify opportunities to enhance compliance and risk management. ▪ Devised value-based tools and processes, validated by external bioethics panel, to help company executives make difficult trade-off decisions in times of simultaneous manufacturing shortages requiring prioritization of medically necessary products.
